I recall there was a conversation some time ago, probably when this was published, on whether the protection PAR has for treatment of BME lesions was enough - and the general agreement was that, yes, it was. As I said before, BME appears in basically all serious cases of OA, so it is impossible for someone to claim to be treating someone with serious OA with pps, but not BME which Paradigm owns the patent for.
Paradigm patent rejection, page-9
-
- There are more pages in this discussion • 79 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $73.55M | |||
| Open | High | Low | Value | Volume |
| 21.0¢ | 22.0¢ | 20.5¢ | $222.5K | 1.035M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 77810 | 21.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.0¢ | 23000 | 2 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |